Archive for the ‘Technology Stocks’ Category

Buzz Stock of the Day: Energy Conversion Devices (ENER)

Friday, March 13th, 2009

The majority of analysts that cover Energy Conversion Devices (Nasdaq: ENER) rate the stock a “hold,” and for good reason.

Market adoption for the company’s photovoltaic thin film technology is growing. The light-weight, flexible laminates are “ideal for commercial and residential rooftop and building integrated PV installations, both of which offer significant growth opportunities,” according to Raymond James (NYSE: RJF) analyst Pavel Molchanov, who has a $37 price target for ENER and projected an EPS growth rate of 25 percent over the next three-years.

ENER could also be one of the big winners from the Obama administration’s stimulus plan. New federal incentives will allow many Americans to immediately lower the price of electricity by installing solar panels on their rooftops, and recoup 30 percent of the installation costs through U.S. treasury grants.

Market sentiment for the Energy Conversion Devices’ prospects is positive, as well. According to the Motley Fool, roughly 93 percent of CAPS members were bullish on ENER, despite the fact that the company cut its June fiscal year revenue guidance from the $455 million to $485 range to a range in the low $400’s.

Shares of ENER are actually up on a trailing-12-month basis, and have outperformed the S&P 500 over the last . The Company has a 67.6 percent gross profit margin, a 7.3 percent return on equity (yoy) and is sitting on about $433 million in cash.

Buzz Stock of the Day: Jacobs Engineering Group (JEC)

Thursday, March 12th, 2009

We love movie trailers, so here’s one for our Buzz Stock of the day:

Jacobs Engineering Group (NYSE: JEC) provides technical, professional, and construction services to industrial, commercial, and governmental customers around the world. The $5 billion company has an operating margin of about 5.6%, and operating cash flow of $539 million.

The Motley Fool listed Jacobs as a stock for the next Great Depression. A key characteristic for these companies to have is the ability to stay out of the debt crisis that’s bringing sectors like finance, automotive, and homebuilding to their knees, according to the Fool.

Jacobs is in a sweet spot of the market–infrastructure–has a definite tailwind, and could be one of the big winners from the new administration’s stimulus plan.

Jacobs reported earnings of $116.4 million, or $0.94 a share in Q1 2009, up more than 18 percent compared with the same quarter last year. The company also increased its backlog by more than $1 billion from a year ago. Jacobs was listed as one of our Top 10 stocks to own in 2009, and we stand by our claim. Expect Jacobs to be one of the big winners of President Barack Obama’s stimulus plan, and out perform the S&P 500 this year.

List of stem cell stocks

Monday, March 9th, 2009

Here’s a great list of companies specializing in stem cell research. The list was originally published here. Some of the companies on the original list are no longer around.

The list below is more accurate than the original.

Aastrom Biosciences Inc. (Nasdaq: ASTM)
Develops patient-specific products for the repair or regeneration of human tissues, using proprietary adult stem cell technology.

AVI Biopharma (Nasdaq: AVII)
A biopharmaceutical company developing drugs to treat life-threatening diseases using third-generation antisense technology.

BrainStorm Cell (Nasdaq: BCLI)
Developer of stem cell therapeutic products based on breakthrough technologies, including their core technology, NurOwn™.

Cord Blood America Inc. (OTCBB: CBAI)
Provides collection, testing, processing, and preservation services of the blood of umbilical cords.

CRYO-CELL (Nasdaq: CCEL)
The world’s oldest & largest family cord blood stem cell bank, for expectant parents for the private collection, processing & cryopreservation of their newborn’s non-controversial U-Cord® stem cells.

Cytori Therapeutics (Frankfurt: XMPA)
Develops proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat, and developed developed its proprietary Celution(TM) System to isolate and concentrate a patient’s own stem and regenerative cells in about an hour.
Geron (Nasdaq: GERN) Develops therapeutic products for oncology that target telomerase; pharmaceuticals that activate telomerase in tissues impacted by senescence, injury or degenerative disease; and cell-based therapies derived from its human embryonic stem cell platform for applications in multiple chronic diseases.
MultiCell (OTCBB: MCET)
Developer of therapeutic products, an adult stem cell company and a supplier of immortalized human cell lines for drug discovery applications.

Stem Cell Thera (TSX.V: SSS)
A biotechnology company focused on the development of its technology platform and intellectual property to selectively induce a patient’s own stem cells to proliferate in the brain.

Stem Cells (Nasdaq: STEM)
Developer of stem cell therapeutics to treat damage to or degeneration of major organ systems such as the central nervous system, liver and pancreas.

ThermoGenesis (Nasdaq: KOOL)
Provides Healthcare professionals with the means to micro-manufacture potentially life-saving and life-enhancing products from individual units of blood.

Buzz Stock of the day- ARAY

Thursday, March 5th, 2009


Companies with disruptive technologies always pop up on our radar. We keep a close eye on them until we start seeing some traction for their products, and then do a little more digging to see if the company has what it takes to be a Buzz Stock.

We’ve had our eye on Accuray, Inc. (Nasdaq: ARAY) for quite some time. The company’s non-invasive CyberKnife Robotic Radiosurgery System has received recognition from both physicians, and customers as of late.

On March 2, Accuray issued a news release that announced “increased interest and continued rapid growth” for CyberKnife. According to the announcement, the number of lung cancer patients treated with CyberKnife grew 52 percent from 2007-2008 in the U.S., and 43 percent worldwide. Additionally the overall number of patients treated with CyberKnife radiosurgery grew to more than 60,000 patients – a 14 percent increase from calendar year 2007 to 2008. In late February, the stock received a 5-star rating from members of the Motley Fool’s CAPS community. The Company has a CAGR of about 52 percent over the past two years and about $110 million of cash in the bank. Currently trading at around $4.00 a share, Accuray could be a good buy at these levels.

Check out this video on CyberKnife to get a better idea of why Accuray is our Buzz Stock of the day.

Buzz Stock of the day: CYIO

Tuesday, February 24th, 2009

Department of Defense contractor CYIOS Corp. (OTCBB: CYIO) announced in late December that it had completed the necessary changes business model to “decrease costs, ensure higher profits and prepare for new contract awards coming in the near future.” In that same announcement, CYIOS stated that it was awaiting new contract awards in excess of $180 million, “which will start at the opening of 2009.”

About a month later, CYIOS issued a news release projecting revenues to triple if not quadruple as new contracts execute. with EPS expected to reach $.08-$.15 by the end of the year. The Company earned $0.06 per-share last year.

Last week, CYIOS announced a comprehensive information technology support contract with the FBI valued at $175 million. The D.C.-based Department of Defense contractor will help design, develop, maintain, enhance, and provide operational support for automated systems.

Shares of CYIO traded for $0.13 as of this post.